Evidence map›Paper›PMID 25147751›Full record

ArticleStroke research and treatment2014

Role of matrix metalloproteinase activity in the neurovascular protective effects of Angiotensin antagonism.

Tauheed Ishrat, Anna Kozak, Ahmed Alhusban, Bindu Pillai, Maribeth H Johnson, Azza B El-Remessy, Adviye Ergul, Susan C Fagan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stroke research and treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tauheed IshratCharlie Norwood VA Medical Center, Augusta, GA 30912, USA ; Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, HM 1212, 1120 15th Street, Augusta, GA 30912, USA.
Anna KozakCharlie Norwood VA Medical Center, Augusta, GA 30912, USA ; Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, HM 1212, 1120 15th Street, Augusta, GA 30912, USA.
Ahmed AlhusbanCharlie Norwood VA Medical Center, Augusta, GA 30912, USA ; Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, HM 1212, 1120 15th Street, Augusta, GA 30912, USA.ORCID 0000-0003-1105-0620
Bindu PillaiCharlie Norwood VA Medical Center, Augusta, GA 30912, USA ; Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, HM 1212, 1120 15th Street, Augusta, GA 30912, USA.
Maribeth H JohnsonDepartment of Biostatistics, Georgia Regents University, Augusta, GA 30912, USA.
Azza B El-RemessyCharlie Norwood VA Medical Center, Augusta, GA 30912, USA ; Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, HM 1212, 1120 15th Street, Augusta, GA 30912, USA ; Vision Discovery Institute, Georgia Regents University, Augusta, GA 30912, USA.
Adviye ErgulCharlie Norwood VA Medical Center, Augusta, GA 30912, USA ; Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, HM 1212, 1120 15th Street, Augusta, GA 30912, USA ; Department of Physiology, Georgia Regents University, Augusta, GA 30912, USA.
Susan C FaganCharlie Norwood VA Medical Center, Augusta, GA 30912, USA ; Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, HM 1212, 1120 15th Street, Augusta, GA 30912, USA ; Department of Neurology, Georgia Regents University, Augusta, GA 30912, USA.
University of Georgia · USAugusta University · US

Funding

Vascular Injury and Recovery in Diabetic Ischemic StrokeR01NS083559 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ERGUL, ADVIYE · 2014 to 2018
$1.9M
Molecular Mechanisms of diabetic retinopathyR01EY022408 · NEI · UNIVERSITY OF GEORGIA · PI EL-REMESSY, AZZA B · 2012 to 2016
$1.5M
Mechanisms of Vascular Protection after Acute StrokeR01NS063965 · NINDS · UNIVERSITY OF GEORGIA · PI FAGAN, SUSAN C · 2009 to 2013
$1.4M
Cerebrovascular mechanisms of ischemic injury in diabetesR03NS054688 · NINDS · AUGUSTA UNIVERSITY · PI ERGUL, ADVIYE · 2007 to 2008
$147k
Cerebral Arteriole Structure/Function in Diabetic Ischemic Brain InjuryI01BX000347 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI ERGUL, ADVIYE · 2009 to 2025
–
Mechanisms and Consequences of Hypertension after StrokeI01BX000891 · VA · CHARLIE NORWOOD VA MEDICAL CENTER · PI FAGAN, SUSAN C · 2011 to 2014
–
BLRD VA I01 BX000347BLRD VA I01 BX000891NEI NIH HHS R01 EY022408NINDS NIH HHS R01 NS063965NINDS NIH HHS R01 NS083559NINDS NIH HHS R03 NS054688
6 · The paper itself

Abstract

Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke. Methods. Wistar rats (n = 9-14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured. Results. Candesartan reduced infarct size and HT when administered alone (P = 0.0011) and in combination with FeTPPs (P = 0.0016). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT (P < 0.0001) and worsened neurologic score (P = 0.028). Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism.

Identifiers

PMID25147751
PMCPMC4134816
OpenAlexW2020683800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.